Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P31749 (
AKT
)
22,954
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Increased expression of the chemokine CX
3
CL1 and its sole receptor, CX
3
CR1 have been correlated with poor pancreatic cancer patient survival and time to recurrence, as well as with pancreatic perineural invasion. We have previously shown that metastasis of prostate and breast cancer is in part driven by CX
3
CL1, and have developed small molecule inhibitors against the CX
3
CR1 receptor that diminish metastatic burden. Here we ask if inhibition of this chemokine receptor affects the phenotype of PDAC tumor cells. Our findings demonstrate that motility, invasion, and contact-independent growth of PDAC cells all increase following CX
3
CL1 exposure, and that antagonism of CX
3
CR1 by the inhibitor
JMS
-17-2 reduces each of these phenotypes and correlates with a downregulation of
AKT
phosphorylation. These data suggest that PDAC tumor cell migration and growth, elements critical in metastatic progression, may susceptible to pharmacologic intervention.
...
PMID:Inhibition of CX
3
CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. 2927 78
